目的 研究Ⅰ型子宫内膜癌组织中长链非编码核糖核酸GAS5（lncRNA-GAS5）的表达及意义。方法 分别采集40例Ⅰ型子宫内膜癌患者及40例因子宫肌瘤等良性病变就诊患者的子宫内膜的组织标本，应用实时荧光定量逆转录聚合酶链反应法分别检测两种不同的子宫内膜组织中lncRNA-GAS5的表达，并结合Ⅰ型子宫内膜癌患者的病理和临床资料将检测的数据进行统计分析。结果 与正常子宫内膜组织相比较lncRNA-GAS5在Ⅰ型子宫内膜癌组织中表达下调，两组间的差异具有统计学意义（P<0.05）。lncRNA-GAS5在期别较晚（Ⅲ~Ⅳ期）的Ⅰ型子宫内膜癌患者中低表达，低于期别较早（Ⅰ~Ⅱ期）的患者；在Ⅰ型子宫内膜癌有淋巴结转移的患者中lncRNA-GAS5呈现低表达，低于无转移者，且差异均具有统计学意义（P<0.05）。在不同病理分级、肌层浸润深度，不同年龄的Ⅰ型子宫内膜癌患者中lncRNA-GAS5表达差异不显著（P>0.05）。结论 子宫内膜癌组织中lncRNA-GAS5表达下调，在期别较晚（Ⅲ~Ⅳ期）及有淋巴结转移的Ⅰ型子宫内膜癌患者中也呈现低表达，lncRNA-GAS5可能在Ⅰ型子宫内膜癌发病和转移过程中起到了抑制作用。
Objective To investigate the expression and significance of lncRNA-GAS5 in typeⅠendometrial cancer tissues. Methods Tissue samples were collected from 40 patients with typeⅠendometrial carcinoma and 40 patients with normal endometrial tissues for benign diseases such as uterine fibroids. The expression of lncRNAP-GAS5 in different endometrial tissues was detected by reverse transcription-polymerase chain reaction. And the detected data were combined with the clinicopathological data of patients with endometrial carcinoma for statistical analyses. Results Compared with normal endometrial tissues, the expression of lncRNA-GAS5 was down-regulated in typeⅠendometrial cancer tissues, and the difference between the two groups was statistically significant(P<0.05). The expression of lncRNAP-GAS5 in typeⅠendometrial cancer tissues of stage Ⅲ~Ⅳ was lower than that in endometrial cancer tissues of stage Ⅰ~Ⅱ. The relative expression quantity of lncRNAP-GAS5 in typeⅠ endometrial cancer with lymph node metastasis was lower than that in typeⅠendometrial cancer without lymph node metastasis with statistically significant(P<0.05). There was no difference in lncRNAP-GAS5 expression between different pathological grades, myometrial inva and ages of typeⅠendometrial carcinoma patients (P>0.05). Conclusions lncRNA-GAS5 was down-regulated in typeⅠendometrial cancer tissues,especially in typeⅠ endometrial cancer at advanced stage (Ⅲ~Ⅳ stage) and with lymph node metastasis, it may play an inhibitory role in the occurrence and metastasis of typeⅠendometrial carcinoma.
1.Bell DW,Ellenson LH.Molecular genetics of endometrial carcinoma.Annu Rev Pathol.2019；14：339-367.
2.Suare AA,Felix AS,Cohn DE.Bokhman redux： endometrial cancer“types”in the 21st century.Gynecol Oncol. 2017；144(2)：243-249.
3.Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017；67(1)：7-30.
4.Hussein YＲ,Soslow ＲA.Molecular insights into the classification of high-grade endometrial carcinoma.Pathology.2018；50(2)：151-161.
5.Liu YR, Tang RX, Huang WT, et al. Long noncoding RNAs in hepatocellular carcinoma： novel insights into their mechanism. World J Hepatol.2015；7(28)：2781-2791.
6.Fatica A, Bozzoni I. Long non-coding RNAs： new players in cell differentiation and development. Nat Rev Genet. 2014；15：7-21.
7.Miao S,W. LK. From discovery to function： the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 2015；36(1)：25-64.
8.Pickard MR, Williams GT. Molecular andcellular mechanisms of action of tumour suppressor GAS5 lncRNA. Genes (Basel). 2015；6： 484-499.
9.Zhang N, Wang AY, Wang XK,et al. GAS5 is downregulated in gastric cancer cells by promoter hypermethylation and regulates adriamycin sensitivity. Eur Rev Med Pharmacol Sci. 2016；20： 3199-3205.
10.Cao L, Chen J, Ou B,et al. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother. 2017；93： 570-579.
11.Luo G, Liu D, Huang C,et al. LncRNA GAS5 inhibits cellular proliferation by targeting P27 kip1. Mol Cancer Res. 2017；15： 789-799.
12.Wen Q, Liu Y, Lyu H,et al. Long noncoding RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer. 2017；27： 1096-1108.
13.殷飞,倪毅.长链非编码 RNA GAS5 在乳腺癌组织中的表达水平及临床意义.中国妇幼保健. 2018；33(23)：5369-5371.
14.Li W, Zhao W, Lu Z, et al. Long noncoding RNA GAS5 promotes proliferation, migration, and invasion byregulation of miR-301a in esophageal cancer. Oncol Res.2018；26：1285-1294.
15.杨雨叶,朱月春.长链非编码RNA GAS5在肿瘤中的作用及其机制.生命的化学.2017；37(6)：1049-1055.
16.李明凯,詹浩炼,吴灵飞.长链非编码RNA GAS5在肿瘤中的研究进展.世界华人消化杂志. 2019；27(3)：175-182.
17.Batista PJ,Chang HY.Long noncoding RNAs：cellular address codes in development and disease. Cell. 2013；152(6)：1298-1307.
18.Hussein YR,Soslow RA.Molecular insights into the classification of high grade endometrial carcinoma.Pathology. 2018；50(2)：151-161.
19.Wang Y,Wang Y,Duan X,et al. Interleukin-1 receptor associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma. J Cell Biochem. 2018；119(3)：2545-2555.
20.Zhou M, Zhang Z, Zhao H, et al.A novel lncＲNA focus expression signature for survival prediction in endometrial carcinoma. BMC Cancer. 2018；18(1)：39.
21.He X, Bao W, Li X, et al. The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. Int Mol Med. 2014；33：325-332.
22.Liu L, Chen X, Zhang Y, et al. Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p. Oncotarget. 2017；8(19)：31386-31394.
23.Zhao L, Li Z, Chen W, et al. LncRNA-H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol Lett. 2017；13(1)：363-369.
24.Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell. 1988；54：787-793.
25.万金华, 陈会平.长链非编码 RNAGAS5在卵巢癌中的表达及对肿瘤侵袭的影响. 实用医学杂志. 2016；32(24)：4062-4065.
26.Long X, Song K, HuH, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovariancancer via GAS5-E2F4-PARP1-MAPK axis.J Exp Clin Cancer Res. 2019；38(1)：345.
27.张洪军,马鹏飞.长链非编码 RNA GAS5 在原发性肝癌中的表达及侵袭作用. 中国现代普通外科进展. 2019；22(3)：169-172.
28.Kamel LM, Atef DM, Mackawy AM, et al. Circulating long non-coding RNA GAS5 and SOX2OT as potential biomarkers for diagnosis and prognosis of non-small cell lung cancer.Biotechnology and Applied Biochemistry. 2019；1764：634-642.
